Turnstone Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	14.55	17.91	35.11	123.76
Short-Term Investments	63.41	76.98	47.33	37.64
Cash & Cash Equivalents	77.96	94.89	82.44	161.4
Cash Growth	21.66%	15.10%	-48.92%	-
Receivables	0	0.19	8.73	6.72
Other Current Assets	7.02	7.47	6.83	9.23
Total Current Assets	84.98	102.55	98	177.34
Property, Plant & Equipment	8.29	9.12	14.36	9.37
Other Long-Term Assets	1.12	1.14	2.58	0.54
Total Long-Term Assets	9.41	10.26	16.94	9.9
Total Assets	94.39	112.82	114.94	187.24
Accounts Payable	1.42	0.04	3.44	0.03
Deferred Revenue	0	0	19.31	72.4
Current Debt	2.03	2.03	1.96	0.66
Other Current Liabilities	9.2	9.91	10.13	-18.11
Total Current Liabilities	12.65	11.97	34.83	54.98
Long-Term Debt	0.69	1.19	3.21	2.02
Other Long-Term Liabilities	1.04	0.99	6.43	40.34
Total Long-Term Liabilities	1.73	2.18	9.63	42.37
Total Liabilities	14.38	14.15	44.46	97.34
Total Debt	2.72	3.21	5.17	2.68
Debt Growth	-42.13%	-37.79%	92.55%	-
Retained Earnings	-196.39	-176.76	-121.56	-90.72
Comprehensive Income	-0.24	-0.12	-0.41	-0.25
Shareholders' Equity	80.01	98.67	-101.47	-81.85
Net Cash / Debt	75.25	91.68	77.28	158.72
Net Cash / Debt Growth	26.70%	18.64%	-51.31%	-
Net Cash Per Share	3.27	7.93	31.10	7.36
Working Capital	72.34	90.58	63.17	122.37
Book Value Per Share	3.48	8.53	-40.84	-4.77

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).